Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.

Mehrvarz Sarshekeh A, Xiong HQ, Iizuka K, Hochster HS, Kopetz S.

Invest New Drugs. 2018 Oct;36(5):895-902. doi: 10.1007/s10637-018-0615-8. Epub 2018 Jun 13.

PMID:
29948357
2.

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.

Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS 4th, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC.

Oncologist. 2017 Dec;22(12):1427-e129. doi: 10.1634/theoncologist.2017-0066. Epub 2017 Sep 21.

3.

[CD69 expression on T cell surface in patients with obstructive sleep apnea hypopnea syndrome].

Chen YH, Wang PF, Wang HJ, Hu X, Li ZY, Xiong HQ.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Feb 20;31(4):301-304. doi: 10.13201/j.issn.1001-1781.2017.04.013. Chinese.

PMID:
29871247
4.

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA.

Cancer. 2008 Oct 15;113(8):2046-52. doi: 10.1002/cncr.23810.

5.

Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.

Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C.

J Pain Symptom Manage. 2007 Sep;34(3):244-52. Epub 2007 May 21.

6.

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA.

Ann Surg Oncol. 2006 Aug;13(8):1035-46. Epub 2006 Jul 24. Review.

PMID:
16865597
7.

Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.

Xiong HQ, Carr K, Abbruzzese JL.

Drugs. 2006;66(8):1059-72. Review.

PMID:
16789792
8.

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.

Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK.

J Clin Oncol. 2006 May 1;24(13):2065-72.

PMID:
16648507
9.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.

J Clin Oncol. 2006 Jun 1;24(16):2505-12. Epub 2006 Apr 24.

PMID:
16636341
10.

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3802-12. Erratum in: Cancer Res. 2010 Jan 15;70(2):852-3.

11.

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA.

J Clin Oncol. 2006 Mar 1;24(7):1145-51.

PMID:
16505434
12.

Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells.

Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ.

Cancer Biol Ther. 2005 Nov;4(11):1263-9. Epub 2005 Dec 1.

PMID:
16319525
13.

Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.

Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HQ, Ho L, Crane CH; Pancreatic Tumor Study Group.

Am J Clin Oncol. 2005 Jun;28(3):227-33.

PMID:
15923793
14.

A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.

Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL.

Cancer Chemother Pharmacol. 2005 Jun;55(6):559-64. Epub 2005 Feb 22.

PMID:
15726370
15.

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):678-89.

16.

Adjuvant therapy for pancreatic cancer: current status and future directions.

Xiong HQ, Abbruzzese JL.

Surg Oncol Clin N Am. 2004 Oct;13(4):737-49, xi. Review.

PMID:
15350945
17.

Molecular targeting therapy for pancreatic cancer.

Xiong HQ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S69-77. Review.

PMID:
15316751
18.

A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL.

Invest New Drugs. 2004 Nov;22(4):459-66.

PMID:
15292716
19.

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL.

J Clin Oncol. 2004 Jul 1;22(13):2610-6.

PMID:
15226328
20.

Novel therapies for pancreatic adenocarcinoma.

Pino SM, Xiong HQ, McConkey D, Abbruzzese JL.

Curr Gastroenterol Rep. 2004 Apr;6(2):119-25. Review.

PMID:
15191689
21.

Novel therapies for pancreatic adenocarcinoma.

Pino SM, Xiong HQ, McConkey D, Abbruzzese JL.

Curr Oncol Rep. 2004 May;6(3):199-206. Review.

PMID:
15066231
23.

Treatment of colorectal cancer metastasis: the role of chemotherapy.

Xiong HQ, Ajani JA.

Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):145-63. Review.

PMID:
15000155
24.

NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells.

Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K.

Int J Cancer. 2004 Jan 10;108(2):181-8.

25.

Experimental animal models of pancreatic carcinogenesis and metastasis.

Wei D, Xiong HQ, Abbruzzese JL, Xie K.

Int J Gastrointest Cancer. 2003;33(1):43-60. Review.

PMID:
12909737
26.

Chemoradiation for resectable gastric cancer.

Xiong HQ, Gunderson LL, Yao J, Ajani JA.

Lancet Oncol. 2003 Aug;4(8):498-505. Review.

PMID:
12901965
27.

Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent advances in pancreatic cancer.

Xiong HQ, Abbruzzese JL, Esumi H, Kosuge T, Kakizoe T, Sugimura T.

Jpn J Clin Oncol. 2003 May;33(5):246-53. No abstract available.

PMID:
12865470
28.

Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.

Xiong HQ, Tran HT, Madden TL, Newman RA, Abbruzzese JL.

Clin Cancer Res. 2003 Jun;9(6):2066-71.

29.

[Functions of neutrophil gelatinase-associated lipocalin in the esophageal carcinoma cell line SHEEC].

Li EM, Xu LY, Cai WJ, Xiong HQ, Shen ZY, Zeng Y.

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Mar;35(3):247-54. Chinese.

PMID:
12621549
30.
31.

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K.

Oncogene. 2003 Jan 23;22(3):319-29.

PMID:
12545153
32.

Epidermal growth factor receptor-targeted therapy for pancreatic cancer.

Xiong HQ, Abbruzzese JL.

Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7. Review.

PMID:
12422311

Supplemental Content

Loading ...
Support Center